Formation Bio vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI-Native Drug Development & Clinical Asset Acceleration
Formation Bio is an AI-native pharmaceutical company that acquires clinical-stage drug assets and accelerates their development to market using proprietary AI and operational technology; raised $372M in a 2024 Series D;
About
Formation Bio (formerly TrialSpark) is a New York-based AI-native pharmaceutical company founded in 2016 by Nicky Popp and Benjamine Liu. The company operates at the intersection of artificial intelligence and drug development, acquiring clinical-stage pharmaceutical assets — compounds that have demonstrated early safety and efficacy in human trials — and applying proprietary AI and operational technology to accelerate their development timelines and reduce costs. Rather than discovering new drug targets from scratch, Formation Bio's model focuses on execution excellence: identifying undervalued clinical assets and getting them to patients faster and more cheaply than traditional pharma development organizations can.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.